Cleared Traditional

K212620 - Citrasate Liquid Acid Concentrate

K212620 is the FDA 510(k) clearance for Citrasate Liquid Acid Concentrate by Fresenius Medical Care Renal Therapies Group, LLC. It is a Class 2 Gastroenterology & Urology device (product code KPO) cleared through the Traditional 510(k) pathway after a 267-day FDA review.

K212620 · Fresenius Medical Care Renal Therapies Group, LLC · Gastroenterology & Urology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 2022
Decision
267d
Days
Class 2
Risk

K212620 is an FDA 510(k) clearance for the Citrasate Liquid Acid Concentrate, NaturaLyte Liquid Acid Concentrate. Classified as Dialysate Concentrate For Hemodialysis (liquid Or Powder) (product code KPO), Class II - Special Controls.

Submitted by Fresenius Medical Care Renal Therapies Group, LLC (Waltham, US). The FDA issued a Cleared decision on May 12, 2022 after a review of 267 days - an extended review cycle.

This device falls under the Gastroenterology & Urology FDA review panel, regulated under 21 CFR 876.5820 - the FDA gastroenterology and urology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Gastroenterology & Urology review framework, consistent with the majority of Class II 510(k) submissions.

View all Fresenius Medical Care Renal Therapies Group, LLC devices

Submission Details

510(k) Number K212620 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 18, 2021
Decision Date May 12, 2022
Days to Decision 267 days
Submission Type Traditional
Review Panel Gastroenterology & Urology (GU)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
137d slower than avg
Panel avg: 130d · This submission: 267d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code KPO Dialysate Concentrate For Hemodialysis (liquid Or Powder)
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 876.5820
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Gastroenterology & Urology devices follow this clearance model.

Regulatory Peers - KPO Dialysate Concentrate For Hemodialysis (liquid Or Powder)

All 49
Devices cleared under the same product code (KPO) and FDA review panel - the closest regulatory comparables to K212620.
Citric Complete Liquid Citric Acid Concentrate
K223431 · Nipro Renal Solutions USA, Corp. · Aug 2023
NIKKICART
K221652 · Renal Care Dialysis Solutions, S.A. DE C.V. · Mar 2023
Hemo-Lyte C Cartridge
K202508 · Di-Chem, Inc. · Aug 2022
HMB32 Dialysis Solution
K212052 · Haemopharm Biofluids S.R.L. · Jul 2021
Nipro Dry Complete Dry Acid Concentrate for Hemodialysis
K193155 · Nipro Renal Solutions USA, Corp. · Nov 2020
Citrasate Dry Acid Concentrate, Granuflo Dry Acid Concentrate
K192209 · Fresenius Medical Care Renal Therapies Group, LLC · May 2020